目的:观察托尼萘酸与阿托伐他汀联合复方丹参注射液治疗酒精性高脂血症综合征的疗效和安全性。方法:21 例酒精 性高脂血症综合征患者均给予维持酸碱平衡、吸氧等常规治疗,在此基础上,给予托尼萘酸片75 mg,口服,每日3 次+阿托伐他汀 钙片20 mg,口服,每日1 次+复方丹参注射液4 ml,加入5%葡萄糖注射液150 ml 中,静脉滴注,每日1 次。疗程均为30 d。观察所 有患者的临床疗效,治疗前及治疗6、12、18、24、30 d 后的丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素 (TBIL)、总胆固醇(TC)、三酰甘油(TG)、红细胞计数(RBC)、血红蛋白(Hb)及不良反应发生情况。结果:患者经治疗后,总有效率 为95.3%,不良反应发生率为28.5%。患者治疗6、12、18、24、30 d 后的ALT、AST、TBIL及治疗12、18、24、30 d 后的TC、TG均显著 低于治疗前,且随时间延长逐渐降低,而治疗12、18、24、36 d 后的RBC及治疗6、12、18、24、36 d 后的Hb均显著高于治疗前,且随 时间延长逐渐升高,差异均有统计学意义(P<0.05)。结论:托尼萘酸与阿托伐他汀联合复方丹参注射液治疗酒精性高脂血症综 合征疗效显著,且安全性较好。
Abstract
OBJECTIVE:To obverse the efficacy and safety of tolynicate and napthylacetic acid and atorvastation combined with Danshen injection in the treatment of alcoholic hyperlipemia syndrome. METHODS:21 patients with alcoholic hyperlipemia syndrome were enrolled. All patients were given maintaining acid-base balance,oxygen inhalation and other conventional treatment. Based on it,they were orally given 75 mg Tolynicate and napthylacetic acid tablet,3 times a day+20 mg Atorvastatin calcium tablet, once a day+4 ml Compound danshen injection,adding into 150 ml 5% Glucose injection by intravenous infusion,once a day. The treatment course for both groups was 30 d. Clinical efficacy,ALT,AST,TBIL,TC,TG,RBC and Hb before and after 6, 12,18,24 and 30 d,and incidence of adverse reactions were observed. RESULTS:After treatment,the total effective rate was 95.3% and incidence of adverse reactions was 28.5%. The ALT,AST and TBIL after 6,12,18,24 and 30 h and TC and TG after 18,24 and 30 h were significantly lower than before and gradually decreased by time;RBC and Hb after 12,18,24 and 30 h were significantly higher than before and gradually increased by time,the differences were statistically significant(P<0.05). CONCLUSIONS: tolynicate and napthylacetic acid and atorvastation combined with Danshen injection is effective in the treatment of alcoholic hyperlipemia syndrome,with good safety.
关键词
托尼萘酸阿托伐他汀复方丹参注射液酒精性高脂血症综合征
Keywords
Tolynicate and napthylacetic acidatorvastatinDanshen injectionAlcoholic hyperlipemia syndrome